

## Curriculum Vitae

**Stefan Endres, Prof., M.D., B.A. (Harvard)**

Phone: 0049-89-5160-7300  
Mobile: 0049-152-0155 9736  
E-mail: endres@lmu.de



Born: June 17, 1957 in Augsburg, Germany  
Married; one daughter of 20 years, one son of 16 years

### Past and Present Leading Positions

- 2011 Appointment as **Visiting Professor Harvard Medical School**, Department of Pathology, April to August 2011
- 2011 Appointment as **Jury Member for European Research Council (ERC)**, Selection Jury Advanced Investigator Grant, Panel Immunology and Infection
- 2009 - **Spokesman of the DFG Graduate Research Centre** “Oligonucleotides in cell biology and therapy” (renewal with 3,535,078 Euro total funding until 2014)
- 2007 - **Dean of Research, Medical Faculty**, Ludwig-Maximilian University, Munich, Germany, for three years; reelection for term 2010 to 2013 (2009 annual budget for research and education: 149 million Euro); excellence university in the German excellence initiative
- 2007 - **Chairman** of the newly formed **Research Committee** of the Medical Faculty
- 2007 - Principal investigator in the excellence cluster **Center of Integrated Protein Science Munich (CIPS-M)**
- 2007 - **LMUexcellent Research Professor** at the University of Munich as one out of eleven grantees
- 2007 - **Member of the Board** of the **Clinical Study Center**, newly established to coordinate clinical studies at the Ludwig-Maximilian University
- 2006 - **Board of Directors (Aufsichtsrat)** of Ludwig-Maximilian University Clinics for five more years (2009 annual budget: 845 million Euro; 9,929 employees)
- 2006 - **Consultant for biotech companies** designing phase II studies for immunotherapy of patients with autoimmune or infectious diseases
- 2005 - 2006 **Member of the Management Board (Vorstand)** of Ludwig-Maximilian University Clinics
- 2003 - **Member of the Ethics Committee** of the State of Bavaria (Bayerische Landesärztekammer)
- 2003 **Board-certified Immunologist** (German Society of Immunology)
- 2003 - 2007 **Principal Investigator** of investigator-initiated phase II study with autologous dendritic cell vaccination for patients with pancreatic cancer
- 2002 - **Member of the Faculty Council** (Fachbereichsrat), Medical Faculty, Ludwig-Maximilian University
- 1998 - 2009 **Chairman, Subcommittee on Drugs in Gastrointestinal Disease**
- 1997 - 2004 **Course Director** teaching program of **Harvard Educational Alliance**
- 1993 - **Member of Committee on Drug Evaluation** (Arzneimittelkommission), Ludwig-Maximilian University Clinics
- 1997 - **Full Professor of Clinical Pharmacology, Director**, Division of Clinical Pharmacology, Ludwig-Maximilian University

## Professional Training

- 1996 **Subspecialty boards Gastroenterology**, senior physician at intensive care unit  
 1993 **Subspecialty boards Intensive Care Medicine**, Attending Physician at the Department of Internal Medicine  
 1992 **Habilitation for Internal Medicine** (Assistant Professor)  
 1991 **Specialty boards Internal Medicine**  
 1988 -1997 **Residency, Subspecialty Fellowship and Research Group Leader** at Medizinische Klinik Innenstadt, Ludwig-Maximilian University  
 1987 - 1988 **Research Fellow** Scholarship at the Department of Infectious Diseases, New England Medical Center, Boston (group of Prof. Charles Dinarello)  
 1984 -1987 **Medical Internship** at Medizinische Klinik Innenstadt, Ludwig-Maximilian University (Director: Prof. Dr. P. C. Scriba)

## Education

- 1984 **M.D.** degree with *magna cum laude*, Ludwig-Maximilian University, Munich, Germany  
 1983 **State Medical Boards**, Munich  
 1982 Core clinical clerkship Internal Medicine at Beth Israel Hospital, **Harvard Medical School**, Boston  
 1979 **Bachelor of Arts degree** with *magna cum laude*, Department of Biochemistry and Immunology, Harvard University  
 1977 - 1979 Two years study at **Harvard University**, Cambridge, Massachusetts  
 1975 Entering **Medical School** at Ludwig-Maximilian University, Munich  
 1967 - 1975 Secondary School **Gymnasium bei St. Anna** (humanistic, modern languages), Augsburg; skipping grade 10.

## Publications

Total of **146** original research papers in peer-reviewed journals, **42** review articles, and 28 books or book chapters. The cumulative journal impact factor is 838,2. The number of total citations is 10,448 and the h-index (Hirsch) is **60**. For a complete list of publications, see [www.klinische-pharmakologie.de](http://www.klinische-pharmakologie.de) → Publikationen. 50 invited lectures, organisation of 17 scientific conferences and five patents or patent applications.

## Top Ten Publications

- Hartmann G, Battiany J, Poeck H, Wagner M, Kerkmann M, Lubenow N, Rothenfusser S, **Endres S**.  
Rational design of new CpG oligonucleotides that combine B cell activation with high IFN- $\alpha$  induction in plasmacytoid dendritic cells.  
*European Journal of Immunology* 2003; 33:1633-41.
- Hornung V, Guenther-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, **Endres S**, Hartmann G.  
Sequence-specific potent induction of IFN- $\alpha$  by short interfering RNA in plasmacytoid dendritic cells through TLR7.  
*Nature Medicine* 2005; 11:263-70.
- Bourquin C, Schreiber S, Beck S, Hartmann G, **Endres S**.  
Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer.  
*International Journal of Cancer* 2006; 118:2790-5.

4. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, **Endres S**, Hartmann G.  
5'-triphosphate RNA is the ligand for RIG-I.  
*Science* 2006; 314:994-997.
5. Bourquin C, Schmidt L, Hornung V, Wurzenberger C, Anz D, Sandholzer N, Schreiber S, Völkl A, Hartmann G, **Endres S**.  
Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T cells and IgG2a response.  
*Blood* 2007; 109:2953-2960.
6. Schmidt A, Schwerd T, Hamm W, Hellmuth J, Cui S, Wenzel M, Hoffmann F, Michallet MC, Besch R, Hopfner KP, **Endres S**, Rothenfusser S.  
5'-triphosphate RNA requires base-paired structures to activate anti-viral signaling via RIG-I.  
*Proceedings of the National Academy of Sciences USA* 2009; 106:12067-72
7. Gross O, Poeck H, Bscheider M, Dostert C, Hanneschlaeger N, **Endres S**, Hartmann G, Tardivel A, Schweighoffer E, Tybulewicz V, Mocsai A, Tschopp J, Ruland J.  
Syk kinase signaling couples to the Nalp3 inflammasome for anti-fungal host defense.  
*Nature* 2009; 459:433-6
8. Anz D, Koelzer VH, Moder S, Thaler R, Schwerd T, Lahl K, Sparwasser T, Besch R, Poeck H, Hornung V, Hartmann G, Rothenfusser S, Bourquin C, **Endres S**.  
RNA oligonucleotides inhibit Treg cell function.  
*Journal of Immunology* 2010; 184:939-46
9. Poeck H, Bscheider M, Gross O, Finger K, Roth S, Rebsamen M, Hanneschläger N, Schlee M, Rothenfusser S, Barchet W, Kato H, Akira S, Inoue S, **Endres S**, Peschel C, Hartmann G, Hornung V, Ruland J.  
Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production.  
*Nature Immunology* 2010; 11:63-9
10. Bourquin C, Hotz C, Noerenberg D, Voelkl A, Heidegger S, Roetzer LC, Storch B, Sandholzer N, Wurzenberger C, Anz D, **Endres S**.  
Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance.  
*Cancer Research* 2011; 71:5123-33.

### **Memberships in Professional Societies**

German Society of Clinical Pharmacology, German Society of Gastroenterology, German Society of Immunology, German Society of Internal Medicine, German Society of Pharmacology and Toxicology, International Cytokine Society, Tumor Center Munich: Study Group Gastrointestinal Tumors

### **Research Cooperations**

S. Akira (Research Institute for Microbial Diseases, Osaka University, Japan); Th. Blankenstein (Charité University Medicine, Berlin), M. Cella (Department of Immunology, University of Washington); C. Dinarello (Department of Infectious Diseases, University of Colorado); G. Firestein (Division of Rheumatology; University of California); G. Hartmann and V. Hornung (University of Bonn); H.-A. Lehr (Institute of Pathology, University of Lausanne); Prof. E. Maraskovsky (Ludwig Institute for Cancer Research, Melbourne); Dr. D. Speiser, (Ludwig Institute for Cancer Research, Lausanne). Joint publications of the Division of Clinical Pharmacology with cooperating institutes in the past five years: 57 research articles.

## Academic Mentoring

Supervised 46 doctoral theses (33 M.D., 13 Ph.D.) and five habilitations in medicine. Two habilitands (G. Hartmann, C. Bourquin) has been awarded full professorships in Bonn, Germany, and Fribourg, Switzerland, respectively; five former doctoral students became assistant or full professors of medicine in Germany.

## Current Research Funding

Funding ID	Period	Amount (in €)
SFB Transregio 36: "Principles and applications of adoptive T cell therapy". PI: S. Endres	2006 to 2010	100,400
DFG Research Professorship, Federal Excellence Program "Clinical Immunopharmacology". PI: S. Endres	2007 to 2012	905,917
Excellence cluster, Cluster of Integrated Protein Science (CIPS-M); Federal Excellence Program. PI: S. Endres	2007 to 2012	200,000
Bavarian Immunotherapy Network (BayImmuNet)	2009 to 2012	200,000
DFG Research Training Group: "Oligonucleotides in cell biology and therapy" (Speaker: S. Endres), second phase	2010 to 2014	3,535,078
Total		€ 4,941,395

Total funding in the past ten years in the Department of Clinical Pharmacology € 9,788,421.

## Awards

- 2007 - LMUexcellent Professorship, Ludwig-Maximilian University
- 2005 - Jury Member of Paul-Martini Prize, Novartis Foundation Prize for Therapeutic Research and of Wilhelm-Vaillant Prize, three out of the five most prestigious medical research prizes of Germany
- 2000 Honour Medal, Munich-Harvard-Educational Alliance
- 1994 Research Stipend, Walter-Marget-Association
- 1986 Research Stipend of the *Deutsche Forschungsgemeinschaft* for post-doctoral research at New England Medical Center, Boston
- 1977 Scholarship of the *Studienstiftung des Deutschen Volkes*
- 1975 Finalist and 2<sup>nd</sup> place, German National Mathematics Competition

## Memberships on Editorial Boards

*International Journal of Immunopharmacology* (USA); *Infection* (D); *Arzneimittelforschung Drug Research* (D; since 2009).

## Frequent Peer Reviewer (Selection)

*Journal of Clinical Investigation* (USA), *International Immunology* (USA), *Journal of Pharmacology and Experimental Therapeutics* (USA), *British Journal of Cancer* (GB), *European Journal of Immunology* (D); *European Journal of Immunogenetics* (D), *Blood* (USA)

